SCHEMBL9944183

SCHEMBL9944183

CC(=O)c1ccc(NC(=O)c2cc(Cl)c(OC3CCCC3)c(OC3CCCC3)c2)cc1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 3/20 0.49
PDE1A P54750 1/20 0.49
PDE1B Q01064 1/20 0.49
PDE1C Q14123 1/20 0.49
PDE4D Q08499 9/20 0.48
PDE4A P27815 8/20 0.48
PDE4B Q07343 8/20 0.48
PDE4C Q08493 8/20 0.48
RORC P51449 1/20 0.46
POLB P06746 2/20 0.42
NPC1 O15118 1/20 0.42
CASP3 P42574 1/20 0.42
RAB9A P51151 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
TAS1R3 Q7RTX0 1/20 0.41
TAS1R1 Q7RTX1 1/20 0.41
TAS1R2 Q8TE23 1/20 0.41
TOP1 P11387 1/20 0.41
MAPT P10636 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9944228 0.98 PDE5A (0.47) PDE5APDE1APDE1BPDE1CPDE4D
SCHEMBL9944192 0.95 PDE5A (0.46) PDE5APDE1APDE1BPDE1CPDE4D
SCHEMBL1458266 0.93 PDE4D (0.49) PDE5APDE1APDE1BPDE1CPDE4D
SCHEMBL9944234 0.92 PDE5A (0.50) PDE5APDE1APDE1BPDE1CPDE4D
SCHEMBL1458110 0.91 PDE4A (0.47) PDE5APDE1APDE1BPDE1CPDE4D
SCHEMBL9944182 0.89 PDE4A (0.54) PDE5APDE1APDE1BPDE1CPDE4D
SCHEMBL9944233 0.89 MAPT (0.50) PDE5APDE1APDE1BPDE1CPDE4D
SCHEMBL9944176 0.89 PDE4D (0.53) PDE5APDE1APDE1BPDE1CPDE4D
SCHEMBL9944229 0.88 HSD11B1 (0.46) PDE5APDE1APDE1BPDE1CPDE4D
SCHEMBL9944227 0.87 PDE4A (0.51) PDE5APDE1APDE1BPDE1CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9447028-B2 Therapeutic aryl-amido-aryl compounds and their use KING'S COLLEGE LONDON (GB) 2016-09-20 US disclosed
US-20160039747-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2016-02-11 US disclosed
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG PDE5A 1361/4885PDE1A 323/4885PDE1B 613/4885
US-20160039747-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG PDE5A 1361/4885PDE1A 323/4885PDE1B 613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.